Supplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited
|
|
- Teresa Booth
- 6 years ago
- Views:
Transcription
1 LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad, Telangana, x1; 120x1 WHO Prequalification Mar-18 Zidovudine 300mg Tablets Macleods Kachigam, Daman, PVDC/PVC/Alu blister; ; 60 Mar-18 Levofloxacin 0mg disp tablet Macleods Block N2 Village Theda, P.O. Lodhimajra, Tehsil Baddi, District:-Solan Himachal pack Alu/Alu strip pack x x Product WHO PQ on the 22nd of February 2018 Mar-18 Artesunate 0mg Suppository Cipla Limited Cipla Limited, D7, MIDC Industrial area Kurkumbh Dist Pune INDIA Alu/Alu 2' Product WHO PQ on the 22nd of February 2018 February 2018 Sofosbuvir 400 mg tablet Limited Limited, Unit-V, Jadcherla, Mahaboobnagar , Telangana State Product WHO PQ on the 07th of February Abacavir (ABC) as sulfate 20 mg / ml Oral Solution Cipla Dec-2017 Rifampicin +Isoniazid + Pyrazinamide 75mg+50mg+ 150mg disp tablet Macleods Oct-17 Kanamycin sulfate 0.5g Powder for Injection Hisun Pharmaceutica ls, China List of delisted products, 06th March /6 Cipla Limited, L-139 to L-146 Verna Goa; Indore Phase II, Unit II, Plot No , Premier Ind. Estate, Hisun Kachigam, Daman (Hangzhou) Co., Xialian Village, Xukou Town, Fuyang City, Hangzhou City, Zhejiang Provine 240ml, 0ml container pack Alu/Alu strip pack 0 (3x), (x), China Glass vial ml Product WHO PQ on the 12th of december 2017
2 Oct-17 Kanamycin sulfate 1 g Powder for Injection Oct-17 Linezolid 600 mg tablet Oct-17 Zidovudine 300mg Tablets Hisun Pharmaceutica ls, China Macleods Pharmaceutica ls, Hisun (Hangzhou) Co., Xialian Village, Xukou Town, Fuyang City, Hangzhou City, Zhejiang Provine Macleods Plock N-2, Vill. Theda, P.O. Lodhimajra, Baddi, Dist. Solan (H.P) Unit- 22-1, Industrial Development Area, Jeedimetla, Hyderabad China Glass vial ml pack; Strip pack *; *, 5*4 60, 500, 600 Oct-17 Lamivudine + Nevirapine + Stavudine 150 mg +200 mg+ 30 mg Tablet Unit- Jeedimetla, Hyderabad, Andhra, ; Unit-V, Mahaboob Nagar, Andhra, 60, 0, 500 Oct-17 Levofloxacin 500mg Tablet Oct-17 Levofloxacin 250mg Tablet Oct-17 Ethambutol + Isoniazid 400mg+150mg Tablet Oct-17 Isoniazid + Rifampicin 75 mg mg Tablet Oct-17 Mai 2017 March March Ethambutol + Isoniazid + Pyrazinamide + Rifampicin 275 mg + 75 mg mg mg Tablet Hetero Europe SL, Spain Hetero Labs, Hetero Europe SL Spain Lupin Strides Arcolab ltd Strides Arcolab ltd Ethionamide 125mg disp tablet Macleods Efavirenz+ Lamivudine + Tenofovir Disoproxil Fumarate 600 mg mg mg Tablet Lamivudine + Nevirapine + Stavudine 150 mg +200 mg+ 30 mg Tablet Lamivudine + Zidovudine 150 mg mg Tablet Varichem Pharmaceutic als Varichem Pharmaceutic als Hetero Labs Unit V Andra Hetero Labs Unit V Andra Aurangabad Strides Arcolab, Bangalore Strides Arcolab, Bangalore; Phase II, Unit II, Sr No. 366, Premier Ind. Estate, Kachigam, Daman Unit III Jeedimetla, Hyderabad & UNIT V, Telengana ; HDPE bottle; Al/PVC/Aclar blister ;HDPE bottle; Al/PVC/Aclar Alu/PVC/PVDC blister ; Alu/PVC/PVdc ; Alu/PVC/PVdc Alu/Alu strip pack 5,; 50; x ; 50; x ,00, 00, 5x6 Deliested WHO PQ list Deliested WHO PQ list Deliested WHO PQ list WHO PQ in the meantime 30 No longer tentatively approved by USFDA Harare Zimbabwe 60 Deliested WHO PQ list Harare Zimbabwe 60 Deliested WHO PQ list List of delisted products, 06th March /6
3 Linezolid 600mg Tablet Macleods Solan Himachal alu/pvc blister ERP validity period until 31 dec The product is classified under CAT-3 and hence will be delisted. Cycloserine 250 mg Capsule Aspen Pharmacare Aspen Pharmacare Port Elizabeth South Africa 0 De listed WHO PQ list Oct 2015 Abacavir (ABC) as sulfate 60 mg Tablet Unit Survey No 313 Bachyupally, Quthubullapur ; 60, 00; Oct 2015 Efavirenz (EFV) 0 mg Capsule Unit Survey No. 313 &314 ; 30; Oct 2015 Zidovudine 60mg Tablet Oct 2015 Efavirenz + [Lamivudine + Stavudine] 600 mg + [150 mg + 30 mg] Tablet Oct 2015 Indinavir (IDV) as Sulfate 400 mg Capsule Oct 2015 Lamivudine + Nevirapine + Stavudine 150 mg +200 mg+ 30 mg Tablet Oct 2015 Lamivudine + Stavudine 150 mg + 30 mg Tablet Oct 2015 Stavudine (d4t) 30 mg Capsule Laboratories Laboratories Laboratories Laboratories Laboratories UNIT- Survey No. 313 and 314, Bachupally Quthubullapur Unit-VII (SEZ), Mahaboob Paonta Sahib, Himachal ; Alu/Alu blister; Cardboard box 60, 00; 2+1; Paonta Sahib, Himachal HDPE Container 90, 180 Paonta Sahib, Himachal, 60 Paonta Sahib, Himachal Paonta Sahib, Himachal ; ; 60 ; 60; 60 Oct 2015 Efavirenz + [Lamivudine + Zidovudine] 600 mg + [150 mg mg] Tablet Laboratories Paonta Sahib, Himachal Alu/Alu blister; Cardboard box blister contains two lamivudine 150mg and zidovudine 300mg tablets and one efavirenz 600mg tablet. Oct 2015 Efavirenz + Emtricitabine + Tenofovir 600 mg mg mg Tablet Emcure Limited Plot No. P-1 & P-2, I.T.-B.T. Park, Phase II, MIDC, Hinjwadi, PUNE 30 Delisted in PEPFAR lists Oct 2015 Ethambutol 400 mg Film coated tablet Svizera Turbe, Navi, Mumbai 00, Oct 2015 Ethambutol + Isoniazid +Rifampicin 275mg +75mg +150mg Tablet Svizera Turbe, Navi, Mumbai 00 Oct 2015 Ethambutol + Isoniazid + Pyrazinamide + Rifampicin 275 mg + 75 mg mg mg Tablet Svizera Turbe, Navi, Mumbai 00 Oct 2015 Isoniazid+Rifampicin 75mg+150mg Tablet Svizera Turbe, Navi, Mumbai Levofloxacin 750mg Tablet IPCA Pithampur Madhya Clarithromycin 250mg Tablet Microlabs Hosur April Cycloserine 250mg Capsule Microlabs Artemether+Lumefantrine mg Dispersible tablet Microlabs Plot No: S-155 to S-159Verna, Goa 30 0,500 92, Sipcot Industrial Complex, Hosur Artesunate+Amodiaquin (as hydrochloride as dihydrate) 25mg+67.5mg FDC tablet Cipla Cipla - Patalganga unit II 8 0 requested since 5 approved products available in the GF list List of delisted products, 06th March /6
4 42005 Artesunate+Amodiaquin (as hydrochloride as dihydrate) 50mg+135mg FDC tablet Cipla Cipla - Patalganga unit II Artesunate+Amodiaquin (as hydrochloride as dihydrate) 0mg+270mg FDC tablet Cipla Cipla - Patalganga unit II Levofloxacin 250mg Tablet Macleods Levofloxacin 500mg Tablet Macleods Block No. 2, Baddi, Solan Levofloxacin 750mg Tablet Macleods Block No. 2, Baddi, Solan Nevirapine 20mg MicroLabs Nevirapine 50mg MicroLabs Nevirapine 0mg MicroLabs Atazanavir+Ritonavir 300mg+0mg Tablet (FDC) Emcure Mefloquine 250mg Tablet Mepha Lamivudine+Tenofovir disoproxil fumarate + Nevirapine ( mg) + 200mg Co-ed tablets Didanosine (ddi) Didanosine (ddi) Didanosine (ddi) Stavudine (d4t) mg / ml 0 mg 200 mg 1 mg / ml Powder for Oral Solution Tablets for Oral Suspension Tablets for Oral Suspension Poweder for Oral Solution Artesunate + (Sulfadoxine+Pyrimethamine) Co ed 0mg+ (500mg+25mg) Tablet Co-blister Guilin Goa Goa Goa ,60, ,60, ,60,90 Hinjwadi, Pune 30 Sofarimex Industria Quimica e Farmaceutica, Agualva-Cacém Limited, Unit VII (SEZ) Andhra Unit Survey 313 & 314, Unit - III Survey No. 313 & 314, Unit - III Survey No. 313 & 314, Unit Survey No. 313 &314 Guilin Co. No. 43 Quilidian road, Guilin Portugal 4, 6 C0 blister Delisted. Mepha is now owned by Acino. Acino discontinued the SRA approval under Mepha. 8 s pack Acino however is still retained 2g, 4g On Voluntary request manufacturer. 60 On Voluntary request manufacturer. 60 On Voluntary request manufacturer. 200ml On Voluntary request manufacturer. China Co-packed (6+3) Linezolid 600mg Tablet Hetero Labs Hetero Labs Limited (Unit-V), Andhra 20, Moxifloxacin (as Hydrochloride) 400mg Tablet Sandoz Sandoz Private Limited, Navi Mumbai PVC/PVdC/Alu blister Lamivudine+Zidovudine 30mg+60mg Tablet (FDC) Microlabs Micro Labs Limited Goa ,0, Raltegravir 400mg Tablet Hetero Labs Hetero Labs Limited (unit-iii) 22-1, IDA Jeedimetla, Hyderabad , A.P., INDIA 60 List of delisted products, 06th March /6
5 41791 Zidovudine 60mg Tablet Microlabs Micro Labs Limited Goa ,0,500, Lopinavir+Ritonavir 40mg/mg Capsule Cipla May Plot L147 to L-147-1, Verna Industrial Estate, Verna, Goa Cycloserine 250mg Capsule Lupin Aurangabad Ritonavir 0mg Tablet Cipla Patalganga Ofloxacin 200mg Tablet Dholka- Gujarat 50, 0, Ofloxacin 400mg Tablet Efavirenz+Lamivudine+Tenofovir disoproxil fumarate 600mg+300mg+300mg Tablets Abacavir (ABC) 20 mg / ml Oral Solution Lamivudine (3TC) mg / ml Oral Solution Nevirapine (NVP) 50 mg /5 ml Oral Suspension Zidovudine 50mg/5ml Oral solution Prothionamide 250mg Tablet Dholka- Gujarat 0500 Limited Unit VII (SEZ) Mahaboob Nagar (DT), Andhra Unit Survey No. 313 &314 Unit III Survey No. 313, Unit III Survey No. 313 and 314 Bachupally Quthubullapur Mandal, Hyderabad Andhra Unit III Survey No. 313, Dholka, Ahmedabad, ml 240ml 240ml 0ml, 240ml Alu/PVC 0 On Voluntary request manufacturer. Reinstated after variation approval On Voluntary request manufacturer. On Voluntary request manufacturer. Reinstated after variation approval in 2015 On Voluntary request manufacturer. Reinstated after variation approval Ethambutol + Isoniazid 400mg+150mg Tablet Lupin Aurangabad Ethambutol + Isoniazid +Rifampicin 275mg +75mg +150mg Tablet Lupin Aurangabad Isoniazid+Rifampicin 75mg+150mg Tablet Dholka, Ahmedabad, Alu/ blister 00, Isoniazid+Rifampicin 150mg+150mg Tablet Lupin Aurangabad Moxifloxacin (as Hydrochloride) 400mg Tablets Hetero Labs Hyderabad, UNIT-V Alu/Alu cold form blister. s Ethambutol + Isoniazid +Rifampicin 275mg +75mg +150mg Tablet Svizera Turbe, Navi, Mumbai Lamivudine+Tenofovir disoproxil fumarate + Nevirapine ( mg) + 200mg Co-ed tablets Macleods Kachigam, Damam cold form Laminate and Aluminium Foil co packed blisters Ethionamide 250mg Tablet Lupin Aurangabad ; AL/LDPE 0; Moxifloxacin 400mg Tablet Macleods Kachigam Daman s Prothionamide 250mg Tablet Lupin Aurangabad 50 List of delisted products, 06th March /6
6 41456 Efavirenz+Emtricitabine+Tenofovir disoproxil fumarate 600mg+200mg+300mg Tablets Hetero Labs Unit V, SEZ,Mahaboob Nagar Dist , Andhra Lamivudine+Nevirapine+Zidovudine 30mg+50mg+60mg Tablet for Oral suspension Cipla Verna Goa 60, Ethambutol + Isoniazid + Pyrazinamide + Rifampicin 275 mg + 75 mg mg mg Tablet Svizera Turbe, Navi, Mumbai Isoniazid+Rifampicin 75mg+150mg Tablet Svizera Turbe, Navi, Mumbai Levofloxacin 250mg Tablet Hetero Labs Hyderabad, UNIT-V PVC/Alu blister Levofloxacin 500mg Tablet Hetero Labs Hyderabad, UNIT-V PVC/Alu blister Ofloxacin 200mg Tablet Microlabs Hosur Ofloxacin 400mg Tablet Microlabs Hosur Pyrazinamide 500mg Tablet Macleods Kachigam, Damam Darunavir 400mg Tablet Hetero Labs UNIT- Hyderabad Darunavir 600mg Tablet Hetero Labs UNIT- Hyderabad Prothionamide 250mg Tablet Microlabs Hosur ; Bottle 14; Darunavir (TCM) 300 mg Tablet Tibotec Inc sen Ortho LLc, Gurabo Puerto Rico 120 by manufacturer Atazanavir 0 mg Capsule Cipla Goa Atazanavir 200 mg Capsule Cipla Goa Atazanavir 300 mg Capsule Cipla Goa Ethambutol 400mg Tablet Svizera Navi Mumbai 491 Ethambutol 0mg Tablet Macleods kachigam, Damam 461 Nevirapine 50 mg Despersible Tablet Cipla Patalganga 461 Nevirapine 0 mg Despersible Tablet Cipla Patalganga HDPE pack; s ; s ; Blsiter ; Blsiter 00; 00;, 60, 00; 60, 00; List of delisted products, 06th March /6
List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)
Edition: Version 11-19th of July 2018 List of A & B Products List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities) As from the version
More informationCategory and Product-level Procurement and Delivery Planning Guide
Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationState of Industry Readiness for the New Demand Following the New Treatment Guidelines
JOINT MEDICINES PATENT POOL & WHO SATELLITE ON BRIDGING THE NEW TREATMENT GAP: WHAT WILL IT TAKE? State of Industry Readiness f the New Demand Following the New Treatment Guidelines Louis J. Riceberg,
More information1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
More informationThe Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
More informationPatent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) A Strategic Option for India
The Open AIDS Journal, 2010, 4, 41-53 41 Open Access Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) A Strategic Option for India Kanikaram Satyanarayana * and Sadhana Srivastava Intellectual
More informationPaediatric ARV Procurement Working Group Progress Review at 31 December 2015
Paediatric ARV Procurement Working Group Progress Review at 31 December 2015 Version 4 March 2015 Updated with complete 2015 data from version presented at the January 27 2016 PAPWG meeting PAPWG Reporting
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lamivudine/Tenofovir Disoproxil * Lamivudine, Tenofovir Disoproxil Fumarate Read all of this leaflet carefully
More informationWHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment
WHO Global Price Reporting Mechanism the importance of data registration for the regulation of antiretrovirals (ARV) and access to treatment Boniface Dongmo Nguimfack HIV/Technology and Commodities 1 AMDS
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lumartem 1 Artemether / Lumefantrine 20mg/120mg tablets Read all of this leaflet carefully before you start
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 7 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lumartem * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You
More informationList of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS OVERVIEW OF PRESENTATION Introduction : lessons learnt Availability ; implications of making paediatric formulations available Remaining challenges in
More informationMonographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
More informationList Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy
Editin: Versin 147-15th f June 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance
More informationMEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)
NOVEMBER 2018 MEDICINES CATALOG GLOBAL DRUG FACILITY (GDF) Ensuring an uninterrupted supply of quality-assured, affordable tuberculosis (TB) medicines and diagnostics to the world. stoptb.org/gdf Stop
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationList Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy
Editin: Versin 148-19th f July 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance
More informationList Of ARV Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy
Editin: Versin 151-01th Nvember 2018 List Of RV Pharmaceutical Prducts classified accrding t the Fund Quality ssurance Plicy The list is an verview f pharmaceutical prducts subject t the Fund Quality ssurance
More informationRecommendations: Agend a no. Recommendations. Institute. New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml
: I approve the minutes of 32 nd SEC (Antimicrobial, Antiviral, Antiparasitic and Antifungal) held on 11.04.2017 at CDSCO HQ New Delhi and recommended the following: Agend New Drugs Division 1 12-34/12-DC
More informationWHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET
WHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET Page 1 of 10 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER filmcoated Tablets 1 Read all of this leaflet carefully before you start taking this medicine
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationSummary of the Report as of 1st February 2017
MINISTRY OF HEALTH PHARMACY DIVISION Stock Status Report 1st February 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders
More informationCURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Lamivudine+Nevirapine+Zidovudine * lamivudine, nevirapine, zidovudine Read all of this leaflet carefully before
More information5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More informationGPRM - Global Price Reporting Mechanism December Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2010 A summary report from the Global Price Reporting Mechanism Contents Background and Methods................................
More informationMINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 2017 A
MINISTRY OF HEALTH PHARMACY DIVISION STOCK STATUS REPORT AS AT 1st August 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders
More informationTransaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to July 2011
Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 28 to July 211 WHO AIDS Medicines and Diagnostic Services Global Price Reporting Mechanism WHO Library Cataloguing-in-Publication
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationUpdate on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
More informationUpdate on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
More informationRecommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
More informationToolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES
Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES June 2008 Table of contents 1. Introduction... 2 2. Data sources... 2 Facility reporting systems...3 Key informant
More information2 Médecins Sans Frontières July 2007 Untangling the Web of Price Reductions
Médecins Sans Frontières www.accessmed-msf.org July 007 Untangling the Web of Price Reductions Table of Contents 3 Table of contents 5 Background 11 Methodology Product Cards 1 How to read the product
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationMINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERY & CHILDREN TANZANIA FOOD AND DRUGS AUTHORITY P.O.
MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERY & CHILDREN TANZANIA FOOD AND DRUGS AUTHORITY P.O. Box 1253, Dodoma, Tanzania Tel: +255 22 2450751, +255 22 2450512, Fax: +255 22 2450793 Website:
More informationreductions Untangling the web of price reductions: eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 1st December 2003
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationreductions Untangling the web of price reductions: 6th Edition eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 6th Edition 19th
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 10 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Rifampicin/Isoniazid/Pyrazinamide/Ethambutol 150mg/75mg/400mg/275mg film-coated Tablets * rifampicin, isoniazid,
More informationWHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization
SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationPrequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationGPRM - Global Price Reporting Mechanism November Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009 A summary report from the Global Price Reporting Mechanism Contents Abbreviations. 5 Table 1 : of first-line
More informationMedicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationAnnexure. Reason for failure with Report No. (in Form-13)& Date Misbranded Report No / Dated
Annexure List of Drugs, Medical Devices and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/, For the Month of September, 2014 Sl. No. Name of Drugs/medica l device/cosmet ics 1 Paracetamol
More informationPACKAGE LEAFLET. Efavirenz 600 mg tablet WHOPAR part 3 April 2010 (Hetero Labs Ltd), HA399 Section 6 updated: May 2016 Section 2 updated: July 2018
PACKAGE LEAFLET Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER Estiva 600 (Efavirenz 600 mg Tablets) * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationCopenhagen, Denmark September 2014
Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active pharmaceutical ingredients 1 Priorities for Product Development
More informationAbacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Duovir* Lamivudine / Zidovudine 150mg/300mg film-coated tablets Read all of this leaflet carefully before you
More informationUpdate to the optimal list of paediatric ARV formulations
UNICEF/NYHQ2011-0262/Christine Nesbitt Update to the optimal list of paediatric ARV formulations 11-12 Sept. 2013 Geneva, Switzerland IATT Meeting Report Geneva, Switzerland, 11-12 September 2013 i IATT
More informationDrug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand
Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.
More informationProgress Report on the Quantification and Planning Exercise for Antiretroviral Medicines in 2013, within the Framework of SUGEMI Implementation
Progress Report on the Quantification and Planning Exercise for Antiretroviral Medicines in 2013, within the Framework of SUGEMI Implementation Prepared by: Dirección de Desarrollo y Fortalecimiento de
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationPACKAGE LEAFLET. Lamivudine/Zidovudine 150/300 mg Tablets WHOPAR part 3 04/2009, version 1.0 Section 6 updated: June 2017 (Mylan Lab.
PACKAGE LEAFLET Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER Lamivudine/Zidovudine 150mg/300mg Tablets * Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationLamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8
LABELLING Page 1 of 8 PARTICULARS TO APPEAR ON THE OUTER PACKAGING Bottle carton label 1. NAME OF THE MEDICINAL PRODUCT Lamivudine 150 mg Tablets * 2. STATEMENT OF ACTIVE SUBSTANCE Each film-coated tablet
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAccess to essential medicines 59
4. 59 4. 4.1 Introduction According to the WHO framework for health systems (1), a well-functioning health system ensures equitable access to essential medical products, vaccines and technologies of assured
More information25 October 2005 INTRODUCTION
Relative market share of different antiretroviral compounds in low and middle income countries in 2004 and 2005: an analysis of 2 public domain data bases Prepared by the AIDS Medicines and Diagnostics
More informationUNICEF/Malawi/2015/Schermbrucker. policy brief 2016 UPDATE
UNICEF/Malawi/2015/Schermbrucker policy brief IATT PAEDIATRIC ARV FORMULARY AND LIMITED-USE LIST: 2016 UPDATE BACKGROUND Delivery of antiretroviral treatment (ART) to children living with HIV is associated
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationPyrazinamide 500 mg Tablets (Macleods Pharmaceuticals Ltd), TB243. WHOPAR part 3 April 2014 Section 6 updated: May 2014 PACKAGE LEAFLET.
PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER Pyrazinamide 500 mg Tablets * Pyrazinamide Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationTransaction Prices for Antiretroviral Medicines from 2010 to Global Price Reporting Mechanism
SUMMARY report AIDS medicines and diagnostics service Transaction Prices for Antiretroviral Medicines from 2010 to 2013 Global Price Reporting Mechanism December 2013 AIDS medicines and diagnostics service
More informationFree Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/3.1.2/14 INGELHEIM A39/34/0605
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 12 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER * Efavirenz, emtricitabine, tenofovir disoproxil fumarate Read all of this leaflet carefully before you start
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPaediatric antiretroviral therapy.
Paediatric antiretroviral therapy. Guidelines exist for the choice of first line agents, but do not cover second line agents, other than recommending regimes of adequate potency. We would follow PENTA
More informationREIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
More informationSupplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir
Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET Page 1 of 9 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Rifampicin/Isoniazid 75 mg/50 mg Dispersible Tablets* Read all of this leaflet carefully before your child
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationMEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
More informationGaps between Policy and Practice in Managing HIV disease in Asia Pacific
Gaps between Policy and Practice in Managing HIV disease in Asia Pacific Dr. N. Kumarasamy Chief Medical Officer YRGCARE Medical Centre Voluntary Health Services Chief-Chennai Antiviral Research and Treatment
More informationIATT Optimal List of Paediatric ARV Formulations: Background and Update
IATT Optimal List of Paediatric ARV Formulations: Background and Update Nandita Sugandhi Clinton Health Access Initiative, USA PADO/IATT Update for ARV Manufacturers October 19, 2015 Overview Rationale
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSupporting Sustained Supply through the Coordinated Procurement of ARVs
Supporting Sustained Supply through the Coordinated Procurement of ARVs ARV Procurement Working Group Newsletter April 2018 Introduction Through quarterly order cycles and business calls, the APWG has
More informationFIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
More informationThe Cost of Antiretrovirals
The Cost of Antiretrovirals Maximizing Value for Money Veronika J. Wirtz, National Institute of Public Health, Cuernavaca, Mexico Steven S. Forsythe, Futures Institute Atanacio Valencia Mendoza, National
More informationPriority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
More information